Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis

Journal of Antibiotics

Volumn 67, Issue 5, 2014, Pages 387-394

  Parikh, Rajesh ^a   Dalwadi, Sonali ^a   Aboti, Pooja ^a   Patel, Leena ^a  

^a CHAROTAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

Antimicrobial; Isoniazid; Macrophage; Nitric oxide; Phagocytosis; Pulmonary; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ISONIAZID; NITRIC OXIDE; POLYCAPROLACTONE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE TECHNIQUE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG UPTAKE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; ISONIAZID MICROPARTICLE; LIVER TOXICITY; LUNG ALVEOLUS MACROPHAGE; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; POLYMERIC MICROPARTICLE; POLYMERIZATION; PRIORITY JOURNAL; RAT;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTITUBERCULAR AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG-INDUCED LIVER INJURY; ISONIAZID; LIVER; LUNG; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; MICROSPHERES; NITRITES; PARTICLE SIZE; PHAGOCYTOSIS; PRIMARY CELL CULTURE; RATS; RATS, WISTAR;

EID: 84901489961     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2014.13     Document Type: Article

References (39)

1. O'Hara, P. & Hickey, A. J. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Manufacture and characterization. Pharm. Res. 17, 955-961 (2000
2. Sung, J. C. et al. Formulation and pharmacokinetics of self-Assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm. Res. 26, 1847-1855 (2009
3. Suarez, S. et al. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J. Antimicrob. Chemother. 48, 431-434 (2001
4. Sharma, R., Saxena, D., Dwivedi, A. K. & Misra, A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm. Res. 18, 1405-1410 (2001
5. Vyas, S., Kannan, M., Jain, S., Mishra, V. & Singh, P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int. J. Pharm. 269, 37-49 (2004
6. Tewes, F., Brillault, J., Couet, W. & Olivier, J. -C. Formulation of rifampicin-cyclodextrin complexes for lung nebulization. J. Control. Release 129, 93-99 (2008
7. Blomberg, B., Spinaci, S., Fourie, B. & Laing, R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull. World. Health. Organ. 79, 61-68 (2001
8. Verma, R. K., Kaur, J., Kumar, K., Yadav, A. B. & Misra, A. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob. Agents Chemother. 52, 3195-3201 (2008
9. Tiwari, S., Chaturvedi, A. P., Tripathi, Y. B. & Mishra, B. Macrophage-specific targeting of isoniazid through mannosylated gelatin microspheres. AAPS PharmSciTech. 12, 900-908 (2011
10. Rojanarat, W. et al. Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies. Int. J. Mol. Sci. 12, 4414-4434 (2011
11. Chow, A. L., Tong, H. Y., Chattopadhyay, P. & Shekunov, B. Particle engineering for pulmonary drug delivery. Pharm. Res. 24, 411-437 (2007
12. Ré, M-I. Formulating drug delivery systems by spray drying. Drying Technol. 24, 433-446 (2006
13. Buckley, S. T., Kim, K-J. & Ehrhardt, C. In Vitro Cell Culture Models for Evaluating Controlled Release Pulmonary Drug Delivery. In Controlled Pulmonary Drug Delivery pp. 417-442 (Springer, 2011
14. Ricciardolo, F. L., Sterk, P. J., Gaston, B. & Folkerts, G. Nitric oxide in health and disease of the respiratory system. Physiol. Rev. 84, 731-765 (2004
15. Zaki, M. H., Akuta, T. & Akaike, T. Nitric oxide-induced nitrative stress involved in microbial pathogenesis. J. Pharmacol. Sci. 98, 117-129 (2005
16. Zhang, X., Goncalves, R. & Mosser, D. M. The isolation and characterization of murine macrophages. Curr. Protoc. Immunol. 83, Chapter 14, Unit 14.1, 1-14 (2008
17. Onoshita, T. et al. The behavior of PLGA microspheres containing rifampicin in alveolar macrophages. Colloids Surf. B Biointerfaces 76, 151-157 (2010
18. Hasegawa, T. et al. Exact determination of phagocytic activity of alveolar macrophages toward polymer microspheres by elimination of those attached to the macrophage membrane. Colloids Surf. B Biointerfaces 63, 209-216 (2008
19. Ohashi, K., Kabasawa, T., Ozeki, T. & Okada, H. One-step preparation of rifampicin/ poly (lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J. Control. Release 135, 19-24 (2009
20. Abate, G., Mshana, R. N. & Miorner, H. Evaluation of a colorimetric assay based on 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2, 1011-1016 (1998
21. Prior, S. et al. In vitro phagocytosis and monocyte-macrophage activation with poly (lactide) and poly (lactide-co-glycolide) microspheres. Eur. J. Pharm. Sci. 15, 197-207 (2002
22. Changsan, N., Nilkaeo, A., Pungrassami, P. & Srichana, T. Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages. J. Drug. Target. 17, 751-762 (2009
23. Muttil, P. et al. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci. 32, 140-150 (2007
24. Zhang, S. & Kawakami, K. One-step preparation of chitosan solid nanoparticles by electrospray deposition. Int. J. Pharm. 397, 211-217 (2010
25. Coowanitwong, I., Arya, V., Kulvanich, P. & Hochhaus, G. Slow release formulations of inhaled rifampin. AAPS J. 10, 342-348 (2008
26. Chow, A. H., Tong, H. H., Chattopadhyay, P. & Shekunov, B. Y. Particle engineering for pulmonary drug delivery. Pharm. Res. 24, 411-437 (2007
27. Hirota, K. et al. Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. J. Control. Release 119, 69-76 (2007
28. Champion, J. A., Walker, A. & Mitragotri, S. Role of particle size in phagocytosis of polymeric microspheres. Pharm. Res. 25, 1815-1821 (2008
29. Champion, J. A., Katare, Y. K. & Mitragotri, S. Particle shape: A new design parameter for micro- and nanoscale drug delivery carriers. J. Control. Release 121, 3-9 (2007
30. Sahoo, S. K., Panyam, J., Prabha, S. & Labhasetwar, V. Residual polyvinyl alcohol associated with poly (d, l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control. Release 82, 105-114 (2002
31. Sharma, R. et al. Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra. J. Antimicrob. Chemother. 59, 499-506 (2007
32. Young, D. B. Stimulate the phagocytes. Tuberculosis (Edinb) 81, 257-258 (2001
33. Kolodziej, H. & Kiderlen, A. F. In vitro evaluation of antibacterial and immunomodulatory activities of Pelargonium reniforme, Pelargonium sidoides and the related herbal drug preparation EPs 7630. Phytomedicine 14, 18 (2007
34. Marcinkiewicz, J. Nitric oxide and antimicrobial activity of reactive oxygen intermediates. Immunopharmacology 37, 35-41 (1997
35. Hirota, K. et al. Stimulation of phagocytic activity of alveolar macrophages toward artificial microspheres by infection with mycobacteria. Pharm. Res. 25, 1420-1430 (2008
36. Nathan, C. F. & Hibbs, Jr J. B. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. Opin. Immunol. 3, 65-70 (1991
37. Murphy, M. P. Nitric oxide and cell death. Biochim. Biophys. Acta 1411, 401-414 (1999
38. Carlisle, R. & Galambos, J. T. The relationship between conventional liver tests, quantitative function tests, and histopathology in cirrhosis. Dig. Dis. Sci. 24, 358-362 (1979
39. Lal, S., Singhal, S., Burley, D. & Crossley, G. Effect of rifampicin and isoniazid on liver function. Br. Med. J. 1, 148 (1972